Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

*This announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the Company's shares will be made in the United States.*

CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Sole Overall Coordinator, Placing Agent and Capital Market Intermediary

國泰君安國際 GUOTAI JUNAN INTERNATIONAL

Reference is made to the announcement of Concord Healthcare Group Co., Ltd. (the "**Company**") dated 22 July 2025 in relation to the placing of 48,723,600 new H shares under the general mandate (the "**Placing Announcement**"). Capitalised terms used herein shall have the same meanings as those defined in the Placing Announcement unless otherwise specified.

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

The Board is pleased to announce that all the Conditions set out in the Placing Agreement have been fulfilled and the Completion took place on 29 July 2025 in accordance with terms and conditions of the Placing Agreement. A total of 48,723,600 Placing Shares have been successfully placed by the Placing Agent to no fewer than six Placees at the Placing Price of HK$5.54 per Placing Share pursuant to the terms and conditions of the Placing Agreement, representing approximately 18.38% of the number of issued H Shares and approximately 6.63% of the number of issued Shares immediately before the Completion, and approximately 15.52% of the number of issued H Shares and approximately 6.22% of the number of issued Shares as enlarged by the allotment and issue of the Placing Shares immediately upon the Completion as at the date of this announcement.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, (i) each of the Placees and their respective ultimate beneficial owner(s) (where applicable) is an Independent Third Party and not connected with the Company and its connected persons; and (ii) none of the Placees has become a substantial shareholder (as defined in the Listing Rules) of the Company upon the Completion.

The Company will subsequently fulfil the corresponding filing procedures in respect of the Placing timely in accordance with relevant rules of the China Securities Regulatory Commission.

Please refer to the Placing Announcement for further details of the Placing.

USE OF PROCEEDS

The net proceeds from the Placing, after deducting the Placing commission and other relevant costs and expenses of the Placing, amounted to approximately HK$258.78 million. The use of net proceeds from the Placing, together with the unutilized net proceeds from the 2025 Placing as of the date of this announcement, is set out below.

		Unutilized net proceeds from the 2025 Placing as of the date of this announcement	**Net proceeds from the Placing** *(HKD in millions)*	**Expected future capital requirements (excluding unutilized proceeds) until 30 June 2026** [(1)]
To fund the construction of Shanghai Concord Medical Cancer Hospital[(2)]		NA	77.634	Not less than 100
To support the capital needs of the Company and its subsidiaries in the medical AI business, including but not limited to daily operation and management expenses, research and development expenses, etc.[(3)]		NA	38.817	Not less than 20
To repay loans provided by financial institutions to the Company and its subsidiaries, including but not limited to principal and interest of working capital loans, principal and interest of fixed asset loans, and financial leasing liabilities[(4)]		28.182	64.695	Not less than 80
To supplement working capital of the Company and its subsidiaries for general corporate purposes	– Payments for suppliers	9.864	27.172	Not less than 17.5
	– Employee salaries and benefits	5.636	15.527	Not less than 10
	– Operational support expenses (maintenance and upgrading of medical equipment, expenses for property utilities, etc.)	4.227	11.645	Not less than 7.5
	– Administrative expenses (market expansion and promotion, travel expenses, administrative expenses, etc.)	4.227	11.645	Not less than 7.5
	– Others	4.227	11.645	Not less than 7.5

Notes:

(1) Please note that these expectations are based on the most current information available and are subject to revision as the Company' s operations evolve.

(2) As at the date of this announcement, Shanghai Concord Medical Cancer Hospital was under construction. Shanghai Concord Medical Cancer Hospital covers a land area of over 47,800 sq.m. and a total planned GFA of over 158,700 sq.m., and has a planned bed count of 400. Shanghai Concord Medical Cancer Hospital will be a Class III hospital providing the multidisciplinary, standardized cancer diagnosis and treatment services featuring precision radiation therapy, covering the entire process of cancer screening, diagnosis and treatment.

(3) Beijing Healthingkon Technology Co., Ltd. (北京和信康科技有限公司) ("**Beijing Healthingkon**"), one of the AI-orientated subsidiaries of the Company, has developed MRI AI-assisted diagnostic systems and PET-CT AI-assisted diagnostic systems, which will support our hospitals, medical professionals and customers in improving diagnosis efficiency and reducing medical costs through the methods of machine-learning. In addition, Beijing Healthingkon has been continuously developing large language model in the vertical field of cancer therapy.

(4) As disclosed in the annual report of the Company for the year ended 31 December 2024, the current liabilities of the Company include RMB372.6 million in bank and other borrowings. In non-current liabilities, bank and other borrowings amount to RMB2.706 billion.

As at the date of this announcement, the net proceeds from the global offering of the Company have been fully utilized.

EFFECTS OF THE PLACING ON SHAREHOLDING STRUCTURE OF THE COMPANY

The number of total issued Shares of the Company has increased from 734,938,416 Shares to 783,662,016 Shares upon the Completion of the Placing. The number of the total issued H Shares has increased from 265,151,024 H Shares to 313,874,624 H Shares upon the Completion of the Placing, and the number of Domestic Shares remains unchanged as to 469,787,392 Domestic Shares.

The table below sets forth the shareholding structure of the Company immediately before and upon the Completion:

	(i) Immediately before the Completion		**(ii) Immediately after the Completion**	
	Number of Shares	*Approximate percentage of total issued Shares (%)*	*Number of Shares*	*Approximate percentage of total issued Shares (%)*
Domestic Shares				
Core connected persons *(Note 1)*	390,052,412	53.07	390,052,412	49.77
Other Domestic Shareholders	79,734,980	10.85	79,734,980	10.17
Sub-total	**469,787,392**	**63.92**	**469,787,392**	**59.95**
H Shares				
Core connected persons *(Note 2)*	63,859,100	8.69	63,859,100	8.15
Placees	–	–	48,723,600	6.22
Other H Shareholders	201,291,924	27.39	201,291,924	25.69
Sub-total	**265,151,024**	**36.08**	**313,874,624**	40.05
Total	**734,938,416**	**100.00**	**783,662,016**	**100.00**

Notes:

1. This represents the sum of (i) 192,274,636 Domestic Shares that Dr. Yang Jianyu, our chairman of the Board, is deemed to be interested; (ii) 120,000,000 Domestic Shares that CICC Jiatai Phase II (Tianjin) Equity Investment Fund Partnership (Limited Partnership) (中金佳泰貳期(天津)股權投資基金合夥企業(有限合夥)) is interested; and (iii) 77,777,776 Domestic Shares that Ningbo Xinyu Jiahui Enterprise Management Co., Ltd. (寧波信鈺嘉慧企業管理有限公司) is interested.

2. This represents 63,859,100 H Shares that Dr. Yang Jianyu, our chairman of the Board, is deemed to be interested.

3. The sum of the shareholding percentage may not be equal to the total percentage due to rounding.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, 29 July 2025

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.